EP1337513A1 — 4-substituted quinolines as antitumor agents
Assigned to AstraZeneca AB · Expires 2003-08-27 · 23y expired
What this patent protects
The invention concerns compounds of formula (I), wherein each of R?1, R2, R3, R4, R5, R6, R8, R9, R10¿ m, n, p, X, Y and Z have any meanings defined in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture o…
USPTO Abstract
The invention concerns compounds of formula (I), wherein each of R?1, R2, R3, R4, R5, R6, R8, R9, R10¿ m, n, p, X, Y and Z have any meanings defined in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-proliferative agent in the treatment of solid tumour disease.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.